肥胖2型糖尿病药物研究进展
投稿时间:2018-09-05  修订日期:2019-01-03  点此下载全文
引用本文:张宇,王鹏源,刘霞.肥胖2型糖尿病药物研究进展[J].药学实践杂志,2019,37(2):97~102
摘要点击次数: 88
全文下载次数: 78
作者单位E-mail
张宇 海军军医大学药学院药理学教研室, 上海 200433  
王鹏源 海军军医大学药学院药理学教研室, 上海 200433  
刘霞 海军军医大学药学院药理学教研室, 上海 200433 lxflying@aliyun.com 
基金项目:重大新药创制科技重大专项(2018ZX09711002-003-015),上海市"科技创新行动计划"生物医药领域科技支撑项目(18431900800);国家自然科学基金(81473259,81773726)
中文摘要:肥胖与糖尿病发病率密切相关,是糖尿病发病率上升的重要原因。如今上市的大部分降糖药物如胰岛素及其类似物、胰岛素促泌剂、胰岛素增敏剂等都会不同程度的增加患者体重,从而加重胰岛素抵抗,增加降糖药物剂量,形成恶性循环,降糖兼具减肥是当今糖尿病新药研发重要趋势。本文概述了肥胖2型糖尿病的流行病学以及目前上市的降糖药物对体重发展的影响,并重点概述了兼具减肥效应的降糖药物的最新靶点,为肥胖2型糖尿病患者的治疗提供潜在新方法。
中文关键词:肥胖2型糖尿病  降糖药  减重  新靶点
 
Research progress on obesity type 2 diabetes mellitus drug
Abstract:Obesity is closely relative to the increase in diabetes incidence. Most of the current hypoglycemic medicines,such as insulin and its analogues,insulin secretion enhancers,insulin sensitizers and so on,would lead to weight gain,thus aggravating insulin resistance and increasing the dosage of hypoglycemic drugs,which had formed a vicious circle. The development of new drugs targeting both reducing blood sugar and controlling weight had attracted much more attention. the epidemiology of obese type 2 diabetes mellitus and the effect of currently available hypoglycemic drugs on weight development had been reviewed in this article,and the latest targets of hypoglycemic medicines with weight loss effects were highlighted,in order to provide a potential approach for the treatment of obese type 2 diabetes mellitus.
keywords:obesity type 2 diabetes  hypoglycemic drugs  weight reduction  new targets
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮